Indeed, the phase II/III RELATIVITY-047 clinical trial evaluated in the first-line setting in patients affected by metastatic or unresectable melanoma, a combination with an anti–LAG3 antibody, relatlimab, and nivolumab, demonstrated a superior PFS for the combination compared nivolumab as a single agent (10.1 vs. 4.6 months, HR 0.75; 95% CI 0.62–0.92; p = 0.006 by the log-rank test), regardless of LAG3 expression [122]. The gene discussed is LAG3; the disease is melanoma.